Concepedia

FDA-approved drug screening in patient-derived organoids demonstrates potential of drug repurposing for rare cystic fibrosis genotypes

Eyleen de Poel, Sacha Spelier, Marne C. Hagemeijer, Peter van Mourik, S.W.F. Suen, Annelotte M. Vonk, Jesse E. Brunsveld, Georgia N. Ithakisiou, Evelien Kruisselbrink, Hugo Oppelaar,

Journal of Cystic Fibrosis · 2023 · 42 citations · 30 references

DOIFull text

Open access

Concepts

References

30

Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i>

Claire Wainwright, J.S. Elborn, Bonnie W. Ramsey et al. · New England Journal of Medicine · 2015 · 1.6K citations · Full text

, , +15

A functional CFTR assay using primary cystic fibrosis intestinal organoids

Johanna F. Dekkers, Caroline L. Wiegerinck, Hugo R. de Jonge et al. · Nature Medicine · 2013 · 997 citations

, , +8

Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis

Johanna F. Dekkers, Gitte Berkers, Evelien Kruisselbrink et al. · Science Translational Medicine · 2016 · 549 citations

, , +8

Tezacaftor–Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis

Steven M. Rowe, Cori Daines, Felix C. Ringshausen et al. · New England Journal of Medicine · 2017 · 511 citations · Full text

, , +13

Oral Mucosal Organoids as a Potential Platform for Personalized Cancer Therapy

Else Driehuis, Sigrid Kolders, Sacha Spelier et al. · Cancer Discovery · 2019 · 420 citations · Full text

, , +15